Results 11 to 20 of about 84,691 (282)
The role of JAK2 abnormalities in hematologic neoplasms.
Hematology Reports, 2009 In 2005, an activating mutation in the Janus kinase 2 (JAK2) was identified in a significant proportion of patients with myeloproliferative neoplasms, mainly polycythemia vera, essential thrombocythemia and primary myelofibrosis.
Mohammed Khalid Alabdulaali
doaj +4 more sources
Autoimmune Complications in Hematologic Neoplasms. [PDF]
Cancers (Basel), 2021 Autoimmune cytopenias (AICy) and autoimmune diseases (AID) can complicate both lymphoid and myeloid neoplasms, and often represent a diagnostic and therapeutic challenge. While autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) are well
Barcellini W, Giannotta JA, Fattizzo B.
europepmc +6 more sources
Hematological Neoplasms with Eosinophilia
Cancers, 2023 The diagnostic assessment of eosinophilias is complex, requiring a multidisciplinary approach and often involving diagnostic challenges. This work aims for a better understanding of the cytomorphological features, immunophenotype, and biological activity
Bernal, R. +4 more
core +7 more sources
GENETIC PREDISPOSITION TO HEMATOLOGIC MALIGNANCIES IN CHILDHOOD AND ADOLESCENCE
Mediterranean Journal of Hematology and Infectious Diseases, 2023 Advances in molecular biology and genetic testing have greatly improved our understanding of the genetic basis of hematologic malignancies and have enabled the identification of new cancer predisposition syndromes. The recognition of a germline mutation
Francesco Fabozzi, Angela Mastronuzzi
doaj +3 more sources
Quality of life and functional capacity during the treatment of hematologic neoplasms [PDF]
Fisioterapia em Movimento, 2018 Introduction: Cancer is a serious pathology with a high incidence and complex diagnoses. Emotional and environmental factors, the deleterious effects of these, and lifestyle affect different outcomes.
Monique Vanderlinde de Souza +3 more
doaj +3 more sources
Survival of European patients diagnosed with lymphoid neoplasms in 2000–2002: results of the HAEMACARE project [PDF]
Haematologica, 2011 Background The European Cancer Registry-based project on hematologic malignancies (HAEMACARE), set up to improve the availability and standardization of data on hematologic malignancies in Europe, used the European Cancer Registry-based project on ...
Rafael Marcos-Gragera +16 more
doaj +2 more sources
Life, 2022 Hematopoietic stem cell aging, through the acquisition of somatic mutations, gives rise to clonal hematopoiesis (CH). While a high prevalence of CH has been described in otherwise healthy older adults, CH confers an increased risk of both hematologic and
Charles Gaulin +2 more
doaj +2 more sources
Brazilian Journal of Oral Sciences, 2017 Introduction: Individuals undergoing onco-hematologic treatment present higher risk for developing oral and/or systemic infections, due to the intense immunosuppression and compromise of the mucosal barriers during treatment. The aim of this study was to
Thaiane Dantas Dias dos Santos +5 more
doaj +3 more sources
Cellular and Molecular Effects of Eribulin in Preclinical Models of Hematologic Neoplasms. [PDF]
Cancers (Basel), 2022 Despite the advances in understanding the biology of hematologic neoplasms which has resulted in the approval of new drugs, the therapeutic options are still scarce for relapsed/refractory patients.
Vicari HP +3 more
europepmc +2 more sources
Concordance of Peripheral Blood and Bone Marrow Next-Generation Sequencing in Hematologic Neoplasms. [PDF]
Adv Hematol, 2022 Objective. Mutational analysis by next-generation sequencing (NGS) obtained by peripheral blood NGS has been of clinical interest to use as a minimally invasive screening tool.
Jumniensuk C +5 more
europepmc +2 more sources